Credent and CardioTech strike technology deal:
This article was originally published in Clinica
Executive Summary
Medical device company Credent has struck a $500,000 technology transfer and licensing deal with Woburn, Massachusetts-based CardioTech International. The exclusive deal, which enables Credent to synthesise Chronoflex RC biodurable polycarbonate-urethane, also involves CardioTech retaining certain rights to Chronoflex RC for the manufacture and marketing of coronary artery bypass grafts. Credent, based in Wrexham, Wales, will use the technology in its current vascular access and peripheral vascular grafts range and in new products.